This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Metastatic Colorectal Cancer
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
-
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States, 35233
Mayo Clinic Arizona, Phoenix, Arizona, United States, 85259
City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010
cCare, Encinitas, California, United States, 92024
USC Norris Cancer Center, Los Angeles, California, United States, 90033
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
UCLA, Los Angeles, California, United States, 90095
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663
Stanford Cancer Center, Stanford, California, United States, 94305-5820
University of Colorado Cancer Center, Aurora, Colorado, United States, 80045
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Hoffmann-La Roche,
Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche
2029-11-07